Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB2 | P07550 | 3/20 | 0.46 |
| ▸ | ADRB1 | P08588 | 3/20 | 0.46 |
| ▸ | ADRB3 | P13945 | 3/20 | 0.46 |
| ▸ | NISCH | Q9Y2I1 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.42 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | PLA2G1B | P04054 | 1/20 | 0.40 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.40 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.38 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22479875 | 0.85 | RIPK1 (0.53) | ADRB2ADRB1ADRB3NISCHKMT2A | |
| SCHEMBL24499218 | 0.82 | MEN1 (0.47) | ADRB2ADRB1ADRB3NISCHKMT2A | |
| SCHEMBL26505546 | 0.82 | MEN1 (0.47) | ADRB2ADRB1ADRB3NISCHKMT2A | |
| SCHEMBL4897371 | 0.82 | ALDH1A1 (0.65) | ADRB2ADRB1ADRB3NISCHKMT2A | |
| SCHEMBL18907906 | 0.82 | HTR2A (0.41) | IRAK4HTR1AHTR7 | |
| SCHEMBL22479876 | 0.81 | MEN1 (0.49) | ADRB2ADRB1ADRB3NISCHKMT2A | |
| SCHEMBL18959734 | 0.80 | ALDH1A1 (0.39) | ADRB2ALDH1A1L3MBTL1LMNAIRAK4 | |
| SCHEMBL18964615 | 0.78 | ALDH1A1 (0.69) | NISCHKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL18907374 | 0.75 | RIPK1 (0.50) | NISCHKMT2AMEN1ALDH1A1GLA | |
| SCHEMBL24498230 | 0.75 | NISCH (0.40) | ADRB2ADRB1ADRB3NISCHKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2021-03-09 | — | — | US | disclosed |
| EP-3380478-B1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO LLC (US) | 2020-12-23 | — | — | EP | disclosed |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | GILEAD APOLLO, LLC (US) | 2020-10-13 | — | — | US | disclosed |
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | Nimbus Apollo, Inc. | 2019-08-08 | — | — | US | disclosed |
| WO-2017091600-A9 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2018-07-19 | — | — | WO | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | Nimbus Apollo, Inc. | 2017-06-15 | — | — | US | disclosed |
| WO-2017091617-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091602-A1 | ESTER ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
| WO-2017091600-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | GILEAD APOLLO, LLC (US) | 2017-06-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170166583-A1 | ESTER ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT2 | ADRB2 4155/4885ADRB1 3097/4885ADRB3 2175/4885 |
| US-20170166582-A1 | PYRAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, PC | ADRB2 3458/4885ADRB1 2675/4885ADRB3 1204/4885 |
| US-20190241582-A1 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ADRB2 3492/4885ADRB1 2741/4885ADRB3 1121/4885 |
| US-10800791-B2 | Triazole ACC inhibitors and uses thereof | ACACA, ACACB, ACAT1 | ADRB2 3492/4885ADRB1 2741/4885ADRB3 1121/4885 |
| US-10941158-B2 | Pyrazole ACC inhibitors and uses thereof | ACACA, ACACB, PC | ADRB2 3458/4885ADRB1 2675/4885ADRB3 1204/4885 |
| US-20170166584-A1 | TRIAZOLE ACC INHIBITORS AND USES THEREOF | ACACA, ACACB, ACAT1 | ADRB2 3492/4885ADRB1 2741/4885ADRB3 1121/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.